May 11, 2018
Adam Rowe recounts a harrowing experience with his mother, who has frontotemporal dementia.
May 4, 2018
Learn about clinical trials, an important and growing part of our funding at the Alzheimer’s Drug Discovery Foundation.
March 14, 2018
ADDF-supported research was at the forefront of the Summit and the National Plan to Address Alzheimer's.
February 21, 2018
While Alzheimer's accounts for more than two-thirds of dementia cases, the ADDF also funds research to prevent and treat the other causes of dementia.
January 30, 2018
For CTE Awareness Day, we highlight our support of diagnostic tools and treatments for this disease.
January 2, 2018
Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.
December 28, 2017
Learn what a biomarker is, why they matter to the ADDF, which biomarkers we have, and which ones we need.
November 28, 2017
With funding from the ADDF since 2004, Dr. Roberta Diaz Brinton has developed what may become the first ever regenerative treatment for Alzheimer's disease.
October 30, 2017
Wednesday marked the beginning of National Alzheimer's Disease Awareness Month and the 10th Clinical Trials on Alzheimer's Disease conference, which featured a record amount of research we supported.
October 24, 2017
Learn why combination therapy holds such promise for treating Alzheimer's disease, and why Amylyx's drug is the first such therapy we are funding.
September 5, 2017
At our 18th Annual Conference on Alzheimer’s Drug Discovery in Jersey City, the impact of our approach will take center stage.
August 30, 2017
Jeanette Arahood explains how her patients inspired her to join our TCS New York City Marathon team.
August 17, 2017
A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.
July 26, 2017
A new study reveals a high percentage of former football players died with CTE, including 99% of NFL players tested.
June 29, 2017
Dr. Lauren Friedman details the three topics that dominated discussions at this year's BIO International Convention.
June 20, 2017
Our CSO Dr. Fillit explains the differences between Alzheimer's and dementia, two terms often used interchangeably.
May 16, 2017
Since 1998, the ADDF has invested over $100 million in the best ideas to cure Alzheimer's. We are seeing the impact of our efforts, with many promising drugs in clinical trials on the way.
April 28, 2017
ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a leukemia drug being tested for treating Alzheimer’s.
March 7, 2017
Longtime supporter Joyce Cowin talks about why she has a new sense of hope about Alzheimer's treatments.
March 6, 2017
Dr. Howard Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials.
February 21, 2017
Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.
February 15, 2017
Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.
January 17, 2017
Discover ORY-2001, a revolutionary epigenetic therapy for Alzheimer's disease being developed by Oryzon Genomics in Barcelona, Spain.
January 10, 2017
In 2016, we made great progress toward finding drugs to prevent and treat Alzheimer’s, as our top five advances demonstrate.
December 15, 2016
We have supported over 20% of all Alzheimer's treatments currently in clinical trials. One of the most promising is C-31, developed by Frank Longo, MD, PhD.
November 28, 2016
Since 1998, the ADDF has invested $97 million in critical research and—with your #GivingTuesday donation—we will reach $100 million this year.
November 25, 2016
Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.
September 21, 2016
On World Alzheimer’s Day, we celebrate the progress made toward finding effective treatments and look toward the future.
September 12, 2016
Dr. Howard Fillit discusses epigenetic treatments, one of the newest and most promising areas of our portfolio.
September 7, 2016
Ernest Scheyder, a returning member of our TCS NYC Marathon team, shares why he is running for Alzheimer’s research and how you can help our dedicated runners.
September 2, 2016
A treatment has reduced beta-amyloid plaques in the brains of patients with Alzheimer’s disease.
July 6, 2016
Karen Mason reflects on her late husband, Tommy Mason, whom she describes as "larger than life," a trait that remained even as he endured the effects of Alzheimer’s.
March 1, 2016
With support from the ADDF, Carmela Abraham, PhD recently founded Klogene to accelerate the development of a new class of drugs to combat Alzheimer’s disease.
February 25, 2016
Grantee Dr. Frank Longo's promising new drug to treat Alzheimer's is on the cover of Time magazine.
January 11, 2016
Executive Director Howard Fillit, MD, looks back at 2015—our most successful year ever—and thanks the supporters and scientists who made it possible.
December 18, 2015
Adam Rowe shares his experience planning his parents' 50th anniversary while accommodating limitations caused by his mother's frontotemporal dementia.
December 1, 2015
For #GivingTuesday 2015, we invite you learn more about our critical work to conquer Alzheimer's disease.
October 8, 2015
Allison Johnson, a member of our TCS New York City Marathon team, shares why she's running to cure Alzheimer's.
June 10, 2015
Investing more in drug discovery and development is the best chance we have for finding a cure for Alzheimer's disease.
May 8, 2015
Adam Rowe reminsces about his mother's voice, the devastating feeling when Alzheimer's disease quiets it. Or silences it completely.
April 30, 2015
Partnerships increase our funding power and our combined expertise—ultimately, ensuring that we can get to a cure for Alzheimer’s and related dementias faster.
April 6, 2015
As a parent, it wouldn't take much evidence for me to keep my children out of high-impact sports like football and soccer. But as a scientist and a physician, I have a different perspective.
March 20, 2015
As part of Brain Injury Awareness Month, we’re shining a spotlight on research into the link between Alzheimer’s disease and traumatic brain injury.
March 16, 2015
Dr. Roberta Diaz Brinton and Dr. Howard Fillit discuss the latest in Alzheimer’s research and drug development in a recent episode of Alzheimer’s Talks.
March 5, 2015
Loss is a natural part of caring for an Alzheimer's patient. These brave men and women facing Alzheimer's have lost many things in their lives. Love isn't one of them.
February 3, 2015
ADDF-funded researchers are preparing for a phase 3 trial of what could become the first drug approved for mild cognitive impairment.
January 15, 2015
In 2014, we had a transformative year, advancing drugs for Alzheimer's, supporting the best science, and ensuring people have information to protect their brain health.
December 18, 2014
The ADDF and the Alzheimer’s Society UK have teamed up to support a trial of an erectile dysfunction drug as a possible treatment for vascular dementia.
December 10, 2014
It’s no secret that the holidays can be a stressful time. For families living with Alzheimer’s, that stress is often magnified.
December 4, 2014
The Cystic Fibrosis Foundation received a record-breaking $3.3 billion return on its early investment in research that led to the first FDA-approved drug to treat the causes of cystic fibrosis.
November 26, 2014
This Thanksgiving, we are grateful for the support of our donors, which has enabled the ADDF to make tremendous progress in our search for a cure for Alzheimer’s disease.
November 18, 2014
Four years ago, I received the shock of a lifetime: my wife of 22 years, B. Smith, was diagnosed with early-onset Alzheimer’s disease.
October 20, 2014
Researchers at Massachusetts General Hospital successfully created a laboratory model of Alzheimer's, which may be a more accurate way to screen prospective drugs.
October 9, 2014
John O’Keefe, May-Britt Moser, and Edvard Moser, have been awarded the 2014 Nobel Prize in Physiology or Medicine for their discoveries of place and grid cells in the brain.
October 7, 2014
Rachel Lane, PhD, shares her passion for Alzheimer's disease research and her progress in training for the TCS NYC Marathon.
October 6, 2014
Leonard A. Lauder explains why he and his brother, Ronald, co-founded the ADDF, and why they need your help to fulfill its mission of conquering Alzheimer's disease.
October 2, 2014
Some research shows an association between lithium exposure and "beneficial" outcomes. Are the benefits enough to warrant widespread use?
September 24, 2014
Presenters at our recent conference shared exciting progress on new Alzheimer's drug targets and biomarkers.
August 18, 2014
New research reveals that a person without the APOE gene—which influences Alzheimer’s risk—can function normally, paving the way for gene therapies.
August 11, 2014
By 2050, more than 1.5 billion people worldwide will be over the age of 65. Alzheimer's threatens both their health and productivity.
July 28, 2014
Our neuroscientists share highlights from their favorite sessions at the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark.
July 22, 2014
Researchers have identified a promising new drug that prevents abnormal blood clots in the brain, reduces cerebral inflammation, and improves memory in preclinical studies.
July 17, 2014
The widespread misconception that Alzheimer's disease is a typical part of aging has serious ramifications for people's health and research into a cure.
June 30, 2014
My husband and I had been together 26 years when he became one of nearly six million North Americans diagnosed with Alzheimer’s disease. Seven years later, I was an Alzheimer’s widow.
June 27, 2014
We joined the Accelerating Medicines Partnership to speed up drug development for Alzheimer's and other major diseases.
June 18, 2014
Are cynical people more likely to develop dementia? A new study in Neurology examines the surprising link between cynicism and dementia.
June 12, 2014
Like many people experiencing Alzheimer's in its early stages, my father began misplacing important objects and forgetting the names of people.
June 10, 2014
Investing in "virtual biotechs" is an efficient way to fund high-risk and high-reward Alzheimer's research.
June 5, 2014
A recent New York Times Op-Ed highlights that, while it's possible to "repurpose" available drugs to treat patients, we don't test them because "no one stands to make money."
May 23, 2014
Dr. Jeffrey Cummings talks about the promise repurposed drugs offer to people with Alzheimer's and other dementias.
May 21, 2014
The ADDF's Dr. Howard Fillit answers questions about Alzheimer's during the 4th Annual Great Ladies Luncheon and Fashion Show.
May 20, 2014
Healthcare professionals rarely screen patients—even those with many risk factors—for cognitive issues or dementia.
May 8, 2014
Aging is the single greatest risk factor for Alzheimer’s disease. The challenge is translating this knowledge into a cure for the disease.
May 6, 2014
As a medical student in the 1970s, I studied hundreds of diseases. But one never even got a mention: Alzheimer’s.
April 22, 2014
A study from Tufts Medical Center adds to the growing body of evidence suggesting that it is possible to lower one’s risk of developing Alzheimer’s disease.
March 28, 2014
We've known for years that the number of deaths caused by Alzheimer's disease has been underreported. A recent study suggests it may be the third-leading cause of death in the U.S.
March 1, 2014
In 2013, the ADDF funded nearly 40 drug research programs around the world. We look forward to continuing to advance the most promising Alzheimer’s research and improving the lives of millions around the world.
August 19, 2013
I recently saw a patient who was afraid he had Alzheimer's disease. A new scan made it easy to give him an accurate diagnosis. So why can't most patients use it?
June 4, 2013
The current costs of dementia care are enormous. But the future costs could create a crippling financial burden on our society, as the number of people diagnosed with dementia is expected to more than double in the next 30 years.